Marie Joyeux-Faure

List of Publications by Year
in descending order

51 papers	1,144 citations	430442 18 h-index	395343 33 g-index
52 all docs	52 docs citations	52 times ranked	1461 citing authors

#	Article	IF	Citations
1	Implantable cardiac devices in sleep apnoea diagnosis: A systematic review and meta-analysis. International Journal of Cardiology, 2022, 348, 76-82.	0.8	4
2	Machine learning and geometric morphometrics to predict obstructive sleep apnea from 3D craniofacial scans. Sleep Medicine, 2022, 95, 76-83.	0.8	10
3	Obstructive sleep apnea, chronic obstructive pulmonary disease and NAFLD: an individual participant data meta-analysis. Sleep Medicine, 2021, 77, 357-364.	0.8	23
4	Baclofen, insomnia and sleep apnea: a dangerous triad?. Sleep Medicine, 2021, 79, 224.	0.8	1
5	Partial failure of CPAP treatment for sleep apnoea: Analysis of the French national sleep database. Respirology, 2020, 25, 104-111.	1.3	18
6	Long-term variations of arterial stiffness in patients with obesity and obstructive sleep apnea treated with continuous positive airway pressure. PLoS ONE, 2020, 15, e0236667.	1.1	6
7	Impact of a Multimodal Telemonitoring Intervention on CPAP Adherence in Symptomatic OSA and Low Cardiovascular Risk. Chest, 2020, 158, 2136-2145.	0.4	21
8	Who May Benefit From Diuretics in OSA?. Chest, 2020, 158, 359-364.	0.4	17
9	Sleep apnoea and endothelial dysfunction: An individual patient data meta-analysis. Sleep Medicine Reviews, 2020, 52, 101309.	3.8	38
10	Valproic acid and sleep apnoea: A disproportionality signal from the WHO pharmacovigilance database. Respirology, 2020, 25, 336-338.	1.3	2
11	Clinical presentation and comorbidities of obstructive sleep apnea-COPD overlap syndrome. , 2020, 15, e0235331.		0
12	Clinical presentation and comorbidities of obstructive sleep apnea-COPD overlap syndrome. , 2020, 15, e0235331.		0
13	Clinical presentation and comorbidities of obstructive sleep apnea-COPD overlap syndrome. , 2020, 15, e0235331.		0
14	Clinical presentation and comorbidities of obstructive sleep apnea-COPD overlap syndrome. , 2020, 15, e0235331.		0
15	Title is missing!. , 2020, 15, e0236667.		0
16	Title is missing!. , 2020, 15, e0236667.		0
17	Title is missing!. , 2020, 15, e0236667.		0
18	Title is missing!. , 2020, 15, e0236667.		0

#	Article	IF	Citations
19	Title is missing!. , 2020, 15, e0236667.		0
20	Title is missing!. , 2020, 15, e0236667.		0
21	Liver Fibrosis, Sleep Apnea and Cardiovascular Events in Stroke Patients. Cerebrovascular Diseases, 2019, 47, 309-310.	0.8	0
22	Diagnosis and management of central sleep apnea syndrome. Expert Review of Respiratory Medicine, 2019, 13, 545-557.	1.0	46
23	Gabapentinoids and sleep apnea syndrome: a safety signal from the WHO pharmacovigilance database. Sleep, 2019, 42, .	0.6	3
24	Multimodal Remote Monitoring of High Cardiovascular Risk Patients With OSA Initiating CPAP. Chest, 2019, 155, 730-739.	0.4	53
25	Baclofen and sleep apnoea syndrome: analysis of VigiBase, the WHO pharmacovigilance database. European Respiratory Journal, 2018, 51, 1701855.	3.1	15
26	Impact of Non-alcoholic Fatty Liver Disease on long-term cardiovascular events and death in Chronic Obstructive Pulmonary Disease. Scientific Reports, 2018, 8, 16559.	1.6	17
27	What is the best treatment strategy for obstructive sleep apnoea-related hypertension?. Hypertension Research, 2018, 41, 1070-1072.	1.5	4
28	Ticagrelor and CentralÂSleep Apnea. Journal of the American College of Cardiology, 2018, 71, 2378-2379.	1.2	21
29	Continuous Positive Airway Pressure Reduces Night-Time Blood Pressure and Heart Rate in Patients With Obstructive Sleep Apnea and Resistant Hypertension: The RHOOSAS Randomized Controlled Trial. Frontiers in Neurology, 2018, 9, 318.	1.1	35
30	Contribution of obstructive sleep apnoea to arterial stiffness: a meta-analysis using individual patient data. Thorax, 2018, 73, 1146-1151.	2.7	26
31	Acquired central hypoventilation followingListeria monocytogenesrhombencephalitis. Thorax, 2017, 72, 763-765.	2.7	2
32	Prevalence of obesity hypoventilation syndrome in ambulatory obese patients attending pathology laboratories. Respirology, 2017, 22, 1190-1198.	1.3	18
33	Nonalcoholic fatty liver disease in chronic obstructive pulmonary disease. European Respiratory Journal, 2017, 49, 1601923.	3.1	56
34	Severe excessive daytime sleepiness induced by hydroxyurea. Fundamental and Clinical Pharmacology, 2017, 31, 367-368.	1.0	3
35	Drugs and obstructive sleep apnoea. British Journal of Clinical Pharmacology, 2017, 83, 2317-2318.	1.1	1
36	Impact of concomitant medications on obstructive sleep apnoea. British Journal of Clinical Pharmacology, 2017, 83, 688-708.	1.1	31

#	Article	IF	Citations
37	Comparison of continuous positive airway pressure and bosentan effect in mildly hypertensive patients with obstructive sleep apnoea: A randomized controlled pilot study. Respirology, 2016, 21, 546-552.	1.3	9
38	Severe Central Sleep Apnea Associated WithÂChronic Baclofen Therapy. Chest, 2016, 149, e127-e131.	0.4	43
39	Intermittent hypoxia in obese Zucker rats: cardiometabolic and inflammatory effects. Experimental Physiology, 2016, 101, 1432-1442.	0.9	18
40	Continuous positive airway pressure treatment impact on memory processes in obstructive sleep apnea patients: a randomized sham-controlled trial. Sleep Medicine, 2016, 24, 44-50.	0.8	16
41	Impact of effective versus sham continuous positive airway pressure on liver injury in obstructive sleep apnoea: Data from randomized trials. Respirology, 2016, 21, 378-385.	1.3	43
42	Drugs influencing acid base balance and bicarbonate concentration readings. Expert Review of Endocrinology and Metabolism, 2016, 11, 209-216.	1.2	3
43	Impact of obstructive sleep apnea treatment by continuous positive airway pressure on cardiometabolic biomarkers: A systematic review from sham CPAP randomized controlled trials. Sleep Medicine Reviews, 2015, 21, 23-38.	3.8	155
44	Response to Statin Therapy in Obstructive Sleep Apnea Syndrome: A Multicenter Randomized Controlled Trial. Mediators of Inflammation, 2014, 2014, 1-10.	1.4	23
45	Atorvastatin protects against deleterious cardiovascular consequences induced by chronic intermittent hypoxia. Experimental Biology and Medicine, 2013, 238, 223-232.	1.1	33
46	Oxidative stress mediates cardiac infarction aggravation induced by intermittent hypoxia. Fundamental and Clinical Pharmacology, 2013, 27, 252-261.	1.0	100
47	Evaluation of the effect of one large dose of erythropoietin against cardiac and cerebral ischemic injury occurring during cardiac surgery with cardiopulmonary bypass: a randomized doubleâ€blind placeboâ€controlled pilot study. Fundamental and Clinical Pharmacology, 2012, 26, 761-770.	1.0	12
48	Erythropoietin improved initial resuscitation and increased survival after cardiac arrest in rats. Resuscitation, 2009, 80, 696-700.	1.3	22
49	Major Role for Hypoxia Inducible Factor-1 and the Endothelin System in Promoting Myocardial Infarction and Hypertension in an Animal Model of Obstructive Sleep Apnea. Journal of the American College of Cardiology, 2009, 53, 1309-1317.	1.2	153
50	Functional assessment of vascular reactivity after chronic intermittent hypoxia in the rat. Respiratory Physiology and Neurobiology, 2006, 150, 278-286.	0.7	43
51	Impact of OSA primary therapy on antihypertensive drugs use. Sleep, 0, , .	0.6	0